Stories about: BioPharm America

BioPharm 2011: Why the life science industry needs Twitter

(Photo: Chinen Keiya/Flickr)

Like many, I have a Facebook page where I share funny travel stories and cute pictures of my cat with friends and family. But for a long time I didn’t understand how such a platform, and others like Twitter, could affect how business is conducted in the life science industry, and how it fit in my own professional life as a hospital technology licensing manager.

I didn’t get it until a tweet from my colleague and fellow blogger Keeley Wray (@Market_Spy) established a direct contact with a regenerative medicine company potentially interested in a cell-based technology in my portfolio. I was surprised: so Twitter isn’t just for celebrities pushing their albums, movies and perfumes to millions of fans? Consequently, six months ago, I enthusiastically joined the Twitterverse (@maude_tessier) and haven’t looked back.

I’m not the only one recognizing the power of social media in the work that pharma, biotech and academic medical institutions do. Last week at the BioPharm America conference, a 90-minute interactive roundtable discussion emphasized the use of social media to help achieve business objectives.

Read Full Story | 3 Comments | Leave a Comment

Vector’s upcoming coverage of BioPharm 2011

Vector and Children’s Hospital Boston’s Technology and Innovation Development Office (TIDO) at will be enthusiastic participants in next week’s BioPharm America conference (Sept 7-9).  In between networking with industry colleagues and pitching technologies developed at Children’s, we’ll be providing blog coverage and live-tweeting from the sessions under the hashtag #BPA11.

Since BioPharm is in Boston this year, we’re also heavily involved as presenters. Bruce Zetter of Children’s Vascular Biology program will speak about cancer biomarkers on a Wednesday panel titled Lessons Learned in Personalized Medicine in Oncology. Leonard Zon, director of Children’s Stem Cell Program, will describe the development of stem-cell-boosting drugs as part of a Friday panel titled Stem Cells and Drug Discovery: Confronting the Translational Imperative.

And Erik Halvorsen, director of Children’s TIDO, is a panelist in Wednesday’s session titled: Pharma’s Interest in Collaborating Early: Flavor of the Month or Viable Business Model?

Halvorsen elaborates on this theme in an interview for the online life sciences journal Partnering News.

Read Full Story | Leave a Comment